Page 3 - Keith Berman News Today

DOJ and SEC Pursue Decision Diagnostics CEO on COVID-19 Testing Fraud Posted on 12/19/2020 The U.S. Justice Department revealed that a federal grand jury has indicted a California chief executive for allegedly concocting a scheme to defraud investors with false claims about a COVID-19 test. The false claim led to investor losses. Keith Berman, 67, the CEO of Decision Diagnostics Inc., was charged with one count of securities fraud and one count of making false statements, the DOJ said. The SEC ...

SEC Charges Biotech Company and CEO with Fraud Concerning COVID-19 Blood Testing Device Washington, D.C.--(Newsfile Corp. - December 18, 2020) - The Securities and Exchange Commission today announced charges against California-based biotechnology company Decision Diagnostics Corp. and its CEO, Keith Berman, with making false and misleading claims in numerous press releases that the company had developed a working, break-through technology that could accurately detect Covid-19 through a quick b...

SEC Lawsuit Alleges Biotech Firm, CEO Misled Investors About COVID-19 Tests The U.S. Securities and Exchange Commission sued Decision Diagnostics Corp. and its chief executive for allegedly misleading investors by promising the biotechnology company could test for COVID-19 with a finger-prick of blood and provide accurate results in less than one minute. In a complaint filed on Thursday in Manhattan federal court, the SEC said Chief Executive Keith Berman made materially false statements betwee...

CEO of medical device company charged in COVID-19 related fraud scheme 4 Shares The chief executive officer of a California-based medical device company was indicted by a federal grand jury in connection with an alleged scheme to defraud investors by making false and misleading statements about the purported development of a new COVID-19 test, leading to millions of dollars in investor losses.  Keith Berman, 67, the CEO of Decision Diagnostics Inc. was charged by indictment with one count of s...

FOR IMMEDIATE RELEASE Washington D.C., Dec. 18, 2020 — The Securities and Exchange Commission today announced charges against California-based biotechnology company Decision Diagnostics Corp. and its CEO, Keith Berman, with making false and misleading claims in numerous press releases that the company had developed a working, break-through technology that could accurately detect Covid-19 through a quick blood test. The SEC temporarily suspended trading in Decision Diagnost...

CEO Charged With Fraud in 15-Second COVID Test Scheme On 12/18/20 at 5:27 PM EST Keith Berman, the CEO of Decision Diagnostics Corporation (DECN), was indicted for securities fraud after investors purchased stock in his company hoping to profit from a revolutionary COVID-19 test which, in reality, did not exist. Berman claimed that his company had developed a test that could detect COVID-19 from a drop of blood within 15 seconds. Berman told investors via press releases that the test would be r...

NEW YORK, Dec 17 (Reuters) - The U.S. Securities and Exchange Commission sued Decision Diagnostics Corp and its chief executive for allegedly misleading investors by promising the biotechnology company could test for COVID-19 with a finger-prick of blood and provide accurate results in less than one minute. In a complaint filed on Thursday in Manhattan federal court, the SEC said Chief Executive Keith Berman made materially false statements between March and June about what he claimed was his c...

SEC sues California biotech company for misleading investors about COVID-19 tests 12/17/2020 | 05:00pm EDT Send by mail : Message : Required fields NEW YORK (Reuters) - The U.S. Securities and Exchange Commission sued Decision Diagnostics Corp and its chief executive for allegedly misleading investors by promising the biotechnology company could test for COVID-19 with a finger-prick of blood and provide accurate results in less than one minute. In a complaint filed on Thursday in Manhattan ...

Decision Diagnostics Corp.: DECN Provides Testing Update for US, Korea and XPRIZE With Plans for Walk-in Donor Study for at-Home GenViro! Saliva Swift :10 Test Kit DECN plans 150 patient donor study to complete its at-home testing kit EUA LOS ANGELES, CA / ACCESSWIRE / December 16, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) www.decisiondiagnostics.co, a leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters through its subsid...